SCOR IN SYSTEMIC LUPUS ERTHEMATOSUS

当前应用程序请求支持，以创建 北方大学系统性红斑狼疮研究（SCOR） 查佩尔山的卡罗莱纳。我们的提议将联合七名调查人员， 以前在SLE研究中的强大背景（Eisenberg，Clarke， 科恩，杜利，福尔克，里夫斯，和温菲尔德）在四个项目针对 进一步了解自身抗体的免疫调节作用 在SLE生产。我们将研究人类疾病和鼠类疾病 模型，我们将联合收割机在临床研究，细胞 免疫学，免疫化学，免疫遗传学，以及 自身抗体和自身抗原。一个行政核心将支持 SCOR的总体方向（主任Eisenberg博士和温菲尔德博士， 助理署长），并为下列人士提供秘书及会计服务 四个项目。该委员会将得到该司的支持， 流变学、多功能关节炎中心和瑟斯顿 关节炎中心，其职能将有效地整合， 通过他们的主管温菲尔德博士来展示这些存在的实体。的项目 SCOR的内容是：项目1：MRL/lpr小鼠的抗Sm B细胞，"Clarke博士， PI，将研究自身抗体基因的免疫遗传学， 小鼠的免疫调节;项目2："程序性细胞死亡和 系统性自身免疫，"科恩博士，PI，这将调查的作用， 自身耐受和自身抗原释放中的细胞凋亡;项目3： "在狼疮性肾炎治疗中保护卵巢功能"，Falk博士和 Dooley，联合PI，将测试化学诱导的暂时性 更年期可以保护免受环磷酰胺的杀菌作用 治疗和下调活动性SLE;和项目4："正反馈 自身抗体产生的调节，"Reeves博士，PI，将分离 基因的几种自身抗原，并研究如何抗体， 蛋白质可以由其他自身抗体诱导。的进一步认识 自身抗体产生的调节最终将允许 设计人类SLE的特异性疗法。

The current application requests support to create a Specialized Center of Research (SCOR) in Systemic Lupus Erythematosus at the University of North Carolina at Chapel Hill. Our proposal will unite seven investigators with previous strong backgrounds in SLE research (Drs. Eisenberg, Clarke, Cohen, Dooley, Falk, Reeves,and Winfield) in four projects directed at furthering our understanding of the immunoregulation of autoantibody production in SLE. We will investigate both human disease and murine models, and we will combine expertise in clinical research, cellular immunology, immunochemistry, immunogenetics, and the molecular biology of autoantibodies and autoantigens. An administrative core will support the overall direction of the SCOR (Dr. Eisenberg, Director, and Dr. Winfield, Assistant Director) and provide secretarial and accounting services for the four projects. The SCOR will receive support from the Division of Rheumatology, the Multipurpose Arthritis Center, and the Thurston Arthritis Center, and its functions will be efficiently integrated with these existent entities through their director, Dr. Winfield. The projects of the SCOR are: Project 1: Anti-Sm B Cells of MRL/lpr Mice," Dr. Clarke, PI, which will investigate the immunogenetics of autoantibody genes and the immunoregulation of the mice; Project 2: "Programmed Cell Death and Systemic Autoimmunity," Dr. Cohen, PI, which will investigate the role of apoptosis in self tolerance and in the release of autoantigens; Project 3: "Preserving Ovarian Function in Lupus Nephritis Therapy," Drs. Falk and Dooley, co-PIs, which will test whether chemically induced temporary menopause can protect against the sterilizing effects of cyclophosphamide therapy and downregulate active SLE; and Project 4: "Positive Feedback Regulation of Autoantibody Production," Dr. Reeves, PI, which will isolate genes for several autoantigens and investigate how antibodies to such proteins can be induced by other autoantibodies. The further understanding of the regulation of autoantibody production will eventually permit the design of specific therapies in human SLE.